Australia News

Found 6,309 articles

• Propanc Biopharma Enters into Research Collaboration Agreement with the University of Jaén

  9/19/2018

  The development of the backup compound will be used for treating patients with limited therapeutic options for the treatment of solid tumors

• Cynata’s Cymerus™ MSCs Ameliorate Cytokine Release Syndrome in Preclinical Study

  9/19/2018

  Cynata Therapeutics Limited is pleased to announce data from a preclinical model demonstrating that its proprietary Cymerus™ mesenchymal stem cells (MSCs) significantly ameliorate the effects of cytokine release syndrome (CRS), a potentially severe and life-threatening adverse reaction to cancer immunotherapy.

• Benitec Biopharma Announces the Appointment of Gregory R. Reyes, M.D., Ph.D. as Senior Scientific Advisor

  9/19/2018

  Benitec Biopharma Limited ("Benitec" or the "Company") (ASX:BLT; NASDAQ: BNTC; NASDAQ: BNTCW), a clinical-stage biotechnology company developing novel genetic medicines via the proprietary DNA-directed RNA interference (ddRNAi) platform combining RNA interference with gene therapy, today announced that Gregory R. Reyes, M.D., Ph.D., has joined the company as Senior Scientific Advisor.

• APEIRON Announces Collaboration with Lead Discovery Center GmbH

  9/19/2018

  Alliance for medicinal chemistry optimization and development of novel checkpoint blockade approach

• Aurora Cannabis Provides Update on Australis Capital Public Listing

  9/14/2018

  Aurora Cannabis Inc. ("Aurora" or the "Company") (TSX: ACB) (OTCQB: ACBFF) (Frankfurt: 21P; WKN: A1C4WM) and Australis Capital Inc. ("Australis") today announced the common shares and warrants (together the "Units") of Australis are expected to commence trading on the Canadian Securities Exchange

• Schizophrenia Breakthrough Discovered at Neuroscience Research Australia (NeuRA)

  9/13/2018

  Professor Cynthia Shannon Weickert at Neuroscience Research Australia (NeuRA) has identified immune cells in greater amounts in the brains of some people with schizophrenia.

• Propanc Biopharma Provides Shareholder Update after Presenting at the 25th Annual NewsMakers in the Biotech Industry Conference

  9/12/2018

  Propanc Biopharma, Inc. today announced that the Company received a positive reception after presenting at the prestigious 25th Annual NewsMakers in the Biotech Industry Conference last Friday, September 7th

• Imugene Completes Phase 1b Cancer Vaccine Trial Recruitment

  9/12/2018

  Imugene Limited today announced the Phase 1b clinical trial of its HER-Vaxx cancer vaccine in HER-2 gastric cancer patients had completed recruitment.

• DEP® irinotecan outperforms in pancreatic cancer model

  9/12/2018

  ​DEP® irinotecan outperforms in pancreatic cancer model

• In Australia, NovaTears® Eye Drops Are Available on the Pharmaceutical Benefits Scheme (PBS) from Now On

  9/12/2018

  Novaliq GmbH, a specialty pharmaceutical company with the first water-free technology platform that transforms poorly soluble drugs into effective therapeutics for ophthalmology, is the manufacturer of NovaTears®, a novel topical treatment of dry eye disease (DED) and meibomian gland dysfunction (MGD).

• Griffith Institute to Collaborate with Australian Health Manufacturer ATP Science

  9/11/2018

  ATP Science Pty Ltd and Research Fellow Dr Miaomiao Liu from the Griffith Institute for Drug Discovery have been awarded the Griffith Sciences Industry Collaborative Grant aimed at developing collaborations with industry partners/end-users.

• Oventus Medical Ltd (ASX:OVN) Appoints Medical Technology Advisory Board to Guide Commercialisation of Sleep Treatment Platform

  9/10/2018

  Appoints Medical Technology Advisory Board to Guide Commercialisation of Sleep Treatment Platform

• MMJ PhytoTech Ltd (ASX:MMJ) MediPharm Signs Customer Contracts Ahead of TSX-V Listing

  9/10/2018

  MMJ PhytoTech Limited is pleased to note the attached three news releases by MediPharm Labs Inc ("MediPharm") providing the details of three customer contracts signed over the past month or so and ahead of its listing on the TSX Venture Exchange ("TSX-V") expected later this month. 

• Cadrock Secures US$5m for Therapy Targeting $35 billion Heart Disease Market

  9/10/2018

  Enrolls first clinical trial patients in Sydney, Australia

• MMJ PhytoTech Ltd (ASX:MMJ) Ontario Cannabis Store Supply Agreements for Investee Companies

  9/10/2018

  MMJ PhytoTech Limited attaches a copy of a news release by the Ontario Cannabis Store ("OCS") confirming that it has entered into recreational cannabis supply agreements with a number of producers, including United Greeneries, a subsidiary of Harvest One Cannabis Inc.

• Regeneus Ltd (ASX:RGS) Receives R&D Tax Incentive of $2.4M

  9/10/2018

  Regeneus Ltd today reported that it has received $2.4m from the Australian Government's Research and Development tax incentive program for activities conducted during the financial year 2018. 

• Cellmid announces Share Purchase Plan completion and in-store launch of évolis® in USA

  9/10/2018

  Cellmid Limited today advised that the Share Purchase Plan ("SPP") announced on 31 July 2018 with an offer price of $0.38 has now closed. 

• Regeneus Ltd (ASX:RGS) FY18 Results and Business Update

  9/7/2018

  Regeneus Ltd is pleased to provide an overview of its results for the financial year ended 30 June 2018. 

• AusCann Makes Major Process Towards Production of Cannabinoid Medicines during FY18

  9/7/2018

  Appendix 4E and Preliminary Final Report 

• New PBS listing for Leukaemia Drug ICLUSIG® (ponatinib)

  9/7/2018

  ICLUSIG to be made available to all refractory/relapsed Ph+ ALL patients from September 1, 2018